Alnylam Suspends Fitusiran Dosing due to Thrombotic Event
The following is an edited version of a press release from Alnylam Pharmaceuticals. To read the press in full, click here.
Alnylam recently became aware of a fatal serious adverse event (SAE) that occurred in a patient with hemophilia A who was receiving fitusiran in the Phase 2 OLE study. As a result, the Company has suspended dosing in all ongoing fitusiran studies pending further review of the safety event and development of a risk mitigation strategy.
Assisting and Advocating for the Bleeding Disorders Community